Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Funds advised by Apax Partners have agreed to acquire the operating subsidiaries of Spanish pharmaceutical firm Invent Farm from a consortium of investors led by Silfurberg, Framtakssjóður Íslands and Horn II.
Subscribe to our email newsletter
The parties did not disclose the terms of the transaction, which is subject to customary closing conditions. The deal is expected to close in the next few months.
Situated in Barcelona, Invent Farma develops, manufactures and markets generic drugs through its subsidiaries Laboratorios Lesvi , Inke and Qualigen
The company also owns and operates manufacturing facilities in Spain. It employs more than 400 people.
Apax Partners partner and co-head of healthcare Steven Dyson said: “We have identified the European generics space as an attractive investment area.
“We will look to support the organic growth of Invent Farma as well as further consolidate the European generics market, as evidenced by our recent announcement of a transaction with Germany’s neuraxpharm.”
Apart from the Invent Farm transaction, funds advised by Apax Partners have also agreed to acquire German pharmaceutical firm neuraxpharm Arzneimittel from ATAX and Neuraxpharm Holding.
Located in Langenfeld near Düsseldorf, neuraxpharm manufactures generic pharmaceutical products to treat central nervous system disorders.
Founded in 1985, the company has a portfolio of 100 differentiated products to serve the CNS patient requirements.